Los Angeles Capital Management LLC Invests $63,000 in Sana Biotechnology, Inc. $SANA

Los Angeles Capital Management LLC purchased a new stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 23,255 shares of the company’s stock, valued at approximately $63,000.

Other institutional investors have also recently made changes to their positions in the company. Viewpoint Capital Management LLC boosted its position in shares of Sana Biotechnology by 19.1% in the second quarter. Viewpoint Capital Management LLC now owns 28,045 shares of the company’s stock worth $77,000 after purchasing an additional 4,500 shares during the period. Bank of New York Mellon Corp grew its position in Sana Biotechnology by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company’s stock worth $578,000 after acquiring an additional 7,230 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in shares of Sana Biotechnology by 26.5% in the 1st quarter. Hsbc Holdings PLC now owns 41,377 shares of the company’s stock worth $65,000 after purchasing an additional 8,673 shares during the period. Rhumbline Advisers increased its position in Sana Biotechnology by 5.4% during the first quarter. Rhumbline Advisers now owns 182,134 shares of the company’s stock valued at $306,000 after acquiring an additional 9,359 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in Sana Biotechnology by 673.8% in the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock worth $30,000 after purchasing an additional 9,501 shares during the last quarter. Institutional investors own 88.23% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Wedbush boosted their price target on Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Citizens Jmp increased their target price on shares of Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research report on Thursday, October 30th. Citigroup reiterated an “outperform” rating on shares of Sana Biotechnology in a research note on Thursday, October 30th. HC Wainwright dropped their price target on Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Wall Street Zen upgraded shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.33.

Sana Biotechnology Stock Down 3.0%

Shares of NASDAQ SANA opened at $3.53 on Wednesday. The business’s 50 day moving average is $4.19 and its two-hundred day moving average is $3.47. Sana Biotechnology, Inc. has a 52-week low of $1.26 and a 52-week high of $7.30. The firm has a market cap of $940.29 million, a price-to-earnings ratio of -3.64 and a beta of 1.94.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.03. Analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.